Literature DB >> 19465013

Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus.

Masumi Ai1, Seiko Otokozawa, Ernst J Schaefer, Bela F Asztalos, Katsuyuki Nakajima, Peter Shrader, Sekar Kathiresan, James B Meigs, Gordon Williams, David M Nathan.   

Abstract

BACKGROUND: Diabetes mellitus is a major risk factor for coronary heart disease (CHD), renal failure, retinopathy, and neuropathy. Lowering glycosylated hemoglobin (HbA1c) as well as low-density lipoprotein-cholesterol (LDL-C) has been associated with a decreased risk of these complications. We evaluated the utility of glycated albumin (GA) and direct LDL-C, 2 novel assay, as compared to HbA1c and calculated LDL-C, in evaluating diabetes control and lipid in a heterogeneous population and in specific subgroups of patients with type 2 diabetes mellitus.
METHODS: We obtained fasting blood samples and measured HbA1c, GA, and direct LDL-C, as well as other parameters, in a multi-ethnic population of 616 male and female patients with type 2 diabetes and 895 non-diabetic controls.
RESULTS: HbA1c and GA levels, which measure different periods of glycemia, had a correlation of r=0.70 (p<0.001), and mean values in patients were 38.7% and 43.4% higher, respectively, than controls in men, and 41.1% and 40.1% higher, respectively, than controls, in women (both p<0.001). Calculated and direct LDL-C values correlated very highly (r=0.96, p<0.001). The correlations between HbA1c and GA, and between calculated and direct LDL-C were similar for subgroups defined by gender, race, age, and other factors.
CONCLUSIONS: Calculated LDL-C provides an accurate assessment of fasting LDL-C compared with a direct measurement in most subjects, except for those with hypertriglyceridemia, and GA correlates with HbA1c in diabetic and non-diabetic subjects and may serve as a reasonable marker of short term diabetic control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19465013      PMCID: PMC3927411          DOI: 10.1016/j.cca.2009.05.015

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  26 in total

1.  Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.

Authors:  Ernst J Schaefer; Judith R McNamara; Timothy Tayler; Jennifer A Daly; Joi L Gleason; Leo J Seman; Andrea Ferrari; Joel J Rubenstein
Journal:  Am J Cardiol       Date:  2004-01-01       Impact factor: 2.778

Review 2.  Oxidative stress: the special case of diabetes.

Authors:  N F Wiernsperger
Journal:  Biofactors       Date:  2003       Impact factor: 6.113

3.  Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method.

Authors:  Takuji Kouzuma; Yumiko Uemastu; Tomomi Usami; Shigeyuki Imamura
Journal:  Clin Chim Acta       Date:  2004-08-16       Impact factor: 3.786

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  The clinical information value of the glycosylated hemoglobin assay.

Authors:  D M Nathan; D E Singer; K Hurxthal; J D Goodson
Journal:  N Engl J Med       Date:  1984-02-09       Impact factor: 91.245

6.  The national glycohemoglobin standardization program: a five-year progress report.

Authors:  R R Little; C L Rohlfing; H M Wiedmeyer; G L Myers; D B Sacks; D E Goldstein
Journal:  Clin Chem       Date:  2001-11       Impact factor: 8.327

7.  Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease.

Authors:  E J Schaefer; M C Audelin; J R McNamara; P K Shah; T Tayler; J A Daly; J L Augustin; L J Seman; J J Rubenstein
Journal:  Am J Cardiol       Date:  2001-11-15       Impact factor: 2.778

8.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

9.  Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.

Authors:  Ernst J Schaefer; Judith R McNamara; Timothy Tayler; Jennifer A Daly; Joi A Gleason; Leo J Seman; Andrea Ferrari; Joel J Rubenstein
Journal:  Am J Cardiol       Date:  2002-10-01       Impact factor: 2.778

10.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleigh; Richard Peto
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

View more
  9 in total

1.  Variants at the endocannabinoid receptor CB1 gene (CNR1) and insulin sensitivity, type 2 diabetes, and coronary heart disease.

Authors:  Jose M de Miguel-Yanes; Alisa K Manning; Peter Shrader; Jarred B McAteer; Anuj Goel; Anders Hamsten; Caroline S Fox; Jose C Florez; Josée Dupuis; James B Meigs
Journal:  Obesity (Silver Spring)       Date:  2011-06-02       Impact factor: 5.002

2.  Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the Kyushu and Okinawa Population Study (KOPS).

Authors:  N Furusyo; T Koga; M Ai; S Otokozawa; T Kohzuma; H Ikezaki; E J Schaefer; J Hayashi
Journal:  Diabetologia       Date:  2011-09-27       Impact factor: 10.122

Review 3.  Glycated albumin: from biochemistry and laboratory medicine to clinical practice.

Authors:  Elena Dozio; Nicola Di Gaetano; Peter Findeisen; Massimiliano Marco Corsi Romanelli
Journal:  Endocrine       Date:  2016-09-13       Impact factor: 3.633

Review 4.  HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature.

Authors:  Esther Y Lee; Peter T Klementowicz; Robert A Hegele; Bela F Asztalos; Ernst J Schaefer
Journal:  J Clin Lipidol       Date:  2012-11-17       Impact factor: 4.766

5.  Serum glycated albumin as a new glycemic marker in pediatric diabetes.

Authors:  Ji Woo Lee; Hyung Jin Kim; Young Se Kwon; Yong Hoon Jun; Soon Ki Kim; Jong Weon Choi; Ji Eun Lee
Journal:  Ann Pediatr Endocrinol Metab       Date:  2013-12-31

6.  Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.

Authors:  Nuntakorn Thongtang; Masumi Ai; Seiko Otokozawa; Thomas V Himbergen; Bela F Asztalos; Katsuyuki Nakajima; Evan Stein; Peter H Jones; Ernst J Schaefer
Journal:  Am J Cardiol       Date:  2011-02-01       Impact factor: 2.778

Review 7.  Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management.

Authors:  Christina M Parrinello; Elizabeth Selvin
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

8.  Clinical study of advanced glycation end products in egyptian diabetic obese and non-obese patients.

Authors:  Mohamed N Amin; Amany A Mosa; Mamdouh M El-Shishtawy
Journal:  Int J Biomed Sci       Date:  2011-09

9.  Diagnostic Accuracy of Protein Glycation Sites in Long-Term Controlled Patients with Type 2 Diabetes Mellitus and Their Prognostic Potential for Early Diagnosis.

Authors:  Sandro Spiller; Yichao Li; Matthias Blüher; Lonnie Welch; Ralf Hoffmann
Journal:  Pharmaceuticals (Basel)       Date:  2018-04-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.